CXCL13 and cancer: In studies with potential therapeutic application, Bodogai et al., have described a novel mechanism in which in vivo targeting of B cells with a conjugate of CXCL13 and CpG oligonucleotides (CXCL13/CpG-ODN) inhibits tBreg generation, resulting in blocking of cancer metastasis.